ICH and USP Agree to Harmonize Metal Impurity Limits
This article was originally published in The Gold Sheet
ICH and USP have announced plans to harmonize their limits in pharmaceuticals for elemental impurities like arsenic, lead, cadmium and mercury. An ICH Q3D Step 4 guideline that sets these limits is imminent.
You may also be interested in...
The USP has launched an initiative to address the nitrosamine crisis by proposing a new general chapter that outlines a set of analytical methods that manufacturers can use to demonstrate their products are free from unsafe levels of these potential carcinogens. The chapter is aligned with the FDA’s guidance on nitrosamine impurities.
The world’s leading drug regulatory authorities aim to agree in a June ICH meeting on final standards for elemental impurities like arsenic, lead, cadmium and mercury. Industry has some ideas on what they should decide.
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”